Business
Anteris Technologies Global Corp. Announces Proposed $200 Million Public Offering of Common Stock and Strategic Investment from Medtronic
MINNEAPOLIS and BRISBANE, Australia, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced that it is offering to sell, subject to market and other conditions, $200 million of shares of its common stock through a proposed underwritten public offering (the “Offer
About this update from Medtronic Plc.
[{"type":"image","alt":"Anteris Technologies Global Corp.","displaySize":"","headline":null,"caption":"Anteris Technologies Global Corp.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":83,"url":"https://media.zenfs.com/en/globenewswire.com/ebb91cde24fc8bfaa2bbd449d64df87a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/8tNysNEA0DQBTcTu5RQZLg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExNjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/ebb91cde24fc8bfaa2bbd449d64df87a","width":300,"height":83}},"lazy":false},{"type":"text","content":"MINNEAPOLIS and BRISBANE, Australia, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced that it is offering to sell, subject to market and other conditions, $200 million of shares of its common stock through a proposed underwritten public offering (the “Offering”). In addition, the Company intends to grant the underwriters a 30-day option to purchase an additional $30 million of shares of common stock from the Company at the public offering price, less underwriting discounts and commissions.","length":747,"tagName":"p"},{"type":"text","content":"In addition, pursuant to a stock purchase agreement, dated January 20, 2026, Anteris has agreed to sell to Medtronic plc (through a wholly owned subsidiary) in a private placement exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), and at a price per share equal to the public offering price in the Offering, up to $90.0 million of shares of common stock, subject to a minimum purchase of 16.0% of the number of shares of common stock outstanding after the Offering and a maximum purchase of 19.99% of the number of shares of common stock outstanding after the Offering (the “Private Placement”). Completion of the Private Placement is contingent on completion of the Offering; however, the Offering is not contingent on the completion of the Private Placement.","length":817,"tagName":"p"},{"type":"text","content":"Anteris intends to use the net proceeds from the Offering, together with its existing cash and cash equivalents and the net proceeds from ...